Benitec Biopharma Inc. (BNTC)Healthcare | Biotechnology | Hayward, United States | NasdaqCM
14.08 USD
+0.62
(4.606%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 14.08 Short-term: ★★★★☆ | Long-term: ★★★☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 18, 2026, 10:55 p.m. EDT
Short-term rebound momentum is building as the stock tests 52-week highs, supported by positive trial data and a recent public offering to fund operations. The stock is technically above key moving averages but carries significant valuation risk given negative earnings and a high short interest ratio. While the immediate catalysts (BB-301 data) justify a cautious long entry, the fundamental value trap remains without positive EPS turning points. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.097060 |
| AutoTheta | 0.097374 |
| AutoARIMA | 0.099512 |
| MSTL | 0.108448 |
Forecast horizon: 45 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 63% |
| H-stat | 1.72 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.274 |
| Excess Kurtosis | -0.46 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Last Dividend Date | 2018-05-31 |
| Debt to Equity Ratio | 0.527 |
| Market Cap | 482,309,088 |
| Forward P/E | -1.49 |
| Beta | 0.12 |
| Website | https://benitec.com |
As of April 18, 2026, 10:55 p.m. EDT: Options flow indicates mild bullish sentiment with higher Open Interest (OI) in call strikes (12.5, 15.0) compared to out-of-the-money puts. March calls show notable OTM positioning at 15.0 despite low volume, suggesting an expectation of a move higher by April 17. Put positioning is minimal and mostly deep OTM (5.0 strike), implying near-term risk sellers are not active. Implied volatility is elevated for short moves (atm_iv 9.97 for April 17 puts vs 1.67 for calls), potentially signaling a larger expected drop if protection is being bought, but overall positioning leans slightly upside. The Ljung-Box p-value suggests strong autocorrelation in returns, but the negative predicted direction (-2.75%) and high H-stat imply the model detects volatility clustering that might dampen immediate trend clarity.
| Date | Dividend | Yield % |
|---|---|---|
| 2018-06-01 | 0.765 | 0.118203 |
| Attribute | Value |
|---|---|
| 52 Week Change | 0.020289898 |
| Address1 | 3,940 Trust Way |
| All Time High | 5,916.0 |
| All Time Low | 1.86 |
| Ask | 14.23 |
| Ask Size | 1 |
| Audit Risk | 10 |
| Average Daily Volume10 Day | 116,410 |
| Average Daily Volume3 Month | 157,446 |
| Average Volume | 157,446 |
| Average Volume10Days | 116,410 |
| Beta | 0.123 |
| Bid | 13.89 |
| Bid Size | 1 |
| Board Risk | 6 |
| Book Value | 5.47 |
| City | Hayward |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 10 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 14.08 |
| Current Ratio | 67.688 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 14.12 |
| Day Low | 13.365 |
| Debt To Equity | 0.527 |
| Dividend Date | 1,574,035,200 |
| Earnings Timestamp | 1,770,903,000 |
| Earnings Timestamp End | 1,778,761,800 |
| Earnings Timestamp Start | 1,778,761,800 |
| Ebitda | -48,295,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -6.127 |
| Enterprise Value | 295,906,016 |
| Eps Forward | -9.42 |
| Eps Trailing Twelve Months | -1.08 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 11.3837 |
| Fifty Day Average Change | 2.6962996 |
| Fifty Day Average Change Percent | 0.23685616 |
| Fifty Two Week Change Percent | 2.0289898 |
| Fifty Two Week High | 17.15 |
| Fifty Two Week High Change | -3.0699997 |
| Fifty Two Week High Change Percent | -0.17900874 |
| Fifty Two Week Low | 9.85 |
| Fifty Two Week Low Change | 4.2299995 |
| Fifty Two Week Low Change Percent | 0.42944157 |
| Fifty Two Week Range | 9.85 - 17.15 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,403,616,600,000 |
| Float Shares | 17,825,433 |
| Forward Eps | -9.42 |
| Forward P E | -1.4946921 |
| Free Cashflow | -4,355,125 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 19 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.02707 |
| Held Percent Institutions | 0.96358 |
| Implied Shares Outstanding | 34,254,908 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Dividend Date | 1,527,811,200 |
| Last Dividend Value | 0.765 |
| Last Fiscal Year End | 1,751,241,600 |
| Last Split Date | 1,690,329,600 |
| Last Split Factor | 1:17 |
| Long Business Summary | Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. Its Silence and Replace, a DNA-directedRNA interference platform combines RNA interference with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The company is developing BB-301, an AAV-based gene therapy designed to silence the expression of the disease-causing gene for the treatment of oculopharyngeal muscular dystrophy related dysphagia. Benitec Biopharma Inc. is headquartered in Hayward, California. |
| Long Name | Benitec Biopharma Inc. |
| Market | us_market |
| Market Cap | 482,309,088 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_4492928 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -44,108,000 |
| Next Fiscal Year End | 1,782,777,600 |
| Non Diluted Market Cap | 484,052,566 |
| Number Of Analyst Opinions | 6 |
| Open | 13.46 |
| Operating Cashflow | -18,426,000 |
| Operating Margins | 0.0 |
| Overall Risk | 10 |
| Payout Ratio | 0.0 |
| Phone | 510 780 0819 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 14.08 |
| Post Market Time | 1,776,456,604 |
| Previous Close | 13.46 |
| Price Hint | 2 |
| Price To Book | 2.5740404 |
| Profit Margins | 0.0 |
| Quick Ratio | 67.447 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.62 |
| Regular Market Change Percent | 4.60624 |
| Regular Market Day High | 14.12 |
| Regular Market Day Low | 13.365 |
| Regular Market Day Range | 13.365 - 14.12 |
| Regular Market Open | 13.46 |
| Regular Market Previous Close | 13.46 |
| Regular Market Price | 14.08 |
| Regular Market Time | 1,776,456,001 |
| Regular Market Volume | 136,594 |
| Return On Assets | -0.22405 |
| Return On Equity | -0.33504 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 4 |
| Shares Outstanding | 34,254,907 |
| Shares Percent Shares Out | 0.0671 |
| Shares Short | 2,305,987 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 2,018,595 |
| Short Name | Benitec Biopharma Inc. |
| Short Percent Of Float | 0.1188 |
| Short Ratio | 10.98 |
| Source Interval | 15 |
| State | CA |
| Symbol | BNTC |
| Target High Price | 32.0 |
| Target Low Price | 17.0 |
| Target Mean Price | 24.16667 |
| Target Median Price | 24.0 |
| Total Cash | 188,790,000 |
| Total Cash Per Share | 5.495 |
| Total Debt | 987,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.08 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 12.698225 |
| Two Hundred Day Average Change | 1.3817749 |
| Two Hundred Day Average Change Percent | 0.108816385 |
| Type Disp | Equity |
| Volume | 136,594 |
| Website | https://benitec.com |
| Zip | 94,545 |